DB
ENVB icon

Danske Bank’s Enveric Biosciences ENVB Stock Holding History

Danske Bank’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 1139
2026
Q1 		$2 Hold
1
– – ﹤0.01% 1140
2025
Q4 		$4 Buy
+1
New +$7 ﹤0.01% 1511

Other funds holding ENVB

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Danske Bank's ENVB Position: Q2 2026 in Review

Danske Bank held its Enveric Biosciences (ENVB) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Danske Bank first reported a position in ENVB in Q4 2025 and has held it in 3 quarters since. The position peaked at $4 in Q4 2025. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • Danske Bank held 1 share of Enveric Biosciences worth $1 as of Q2 2026.
  • Danske Bank left its Enveric Biosciences share count unchanged in Q2 2026.
  • Enveric Biosciences made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1139 holding.
  • Danske Bank first reported a position in Enveric Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Danske Bank's Enveric Biosciences position peaked at $4 in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.